Pittenger & Anderson’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$535K Buy
6,196
+262
+4% +$23.3K 0.02% 198
2026
Q2
$537K Sell
5,934
-20,252
-77% -$1.7M 0.02% 192
2026
Q1
$2.1M Buy
26,186
+8,669
+49% +$715K 0.08% 139
2025
Q4
$1.49M Buy
17,517
+516
+3% +$42.3K 0.06% 148
2025
Q3
$1.32M Buy
17,001
+1,887
+12% +$147K 0.05% 154
2025
Q2
$1.18M Hold
15,114
– – 0.04% 151
2025
Q1
$1.1M Buy
15,114
+100
+0.7% +$7.16K 0.04% 149
2024
Q4
$1.11M Buy
15,014
+5,609
+60% +$393K 0.04% 153
2024
Q3
$621K Sell
9,405
-8,761
-48% -$637K 0.02% 175
2024
Q2
$1.68M Buy
18,166
+7,461
+70% +$661K 0.07% 143
2024
Q1
$1.02M Buy
10,705
+3,887
+57% +$327K 0.04% 153
2023
Q4
$520K Buy
+6,818
New +$474K 0.02% 177

Other funds holding EW

Pittenger & Anderson's EW Position: Q3 2026 in Review

Pittenger & Anderson increased its Edwards Lifesciences (EW) stake by 4.4% in Q3 2026, buying an estimated $23.3K and bringing the position to 6,196 shares worth $535K. The position accounts for 0.02% of the portfolio, ranked #198.

Pittenger & Anderson first reported a position in EW in Q4 2023 and has held it in 12 quarters since. The position peaked at $2.1M in Q1 2026. 1,344 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Pittenger & Anderson held 6,196 shares of Edwards Lifesciences worth $535K as of Q3 2026.
  • Pittenger & Anderson bought 262 Edwards Lifesciences shares in Q3 2026, an estimated $23.3K.
  • Edwards Lifesciences made up 0.02% of Pittenger & Anderson's portfolio in Q3 2026, its #198 holding.
  • Pittenger & Anderson first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 12 quarters since.
  • Pittenger & Anderson's Edwards Lifesciences position peaked at $2.1M in Q1 2026.
  • 1,344 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Pittenger & Anderson's 13F filing for Q3 2026, filed 2 Nov 2026.